平松 憲AKIRA HIRAMATSU

Last Updated :2018/11/01

所属・職名
病院(医) 消化器診療科 助教
メールアドレス
akirahhiroshima-u.ac.jp
その他連絡先
広島市南区霞1丁目2番3号 研究棟AA203
TEL: 082-257-5191 FAX: 082-257-5194
自己紹介
肝硬変の栄養などを研究しています。

基本情報

主な職歴

  • 2008年04月01日, 広島大学, 病院, 助教

学歴

  • 広島大学, 大学院医歯薬学総合研究科, 日本, 2002年04月, 2007年03月
  • 広島大学, 医学部, 医学科, 日本, 1991年04月, 1997年03月

学位

  • 博士(医学) (広島大学)

担当主専攻プログラム

  • 医学プログラム

研究分野

  • 医歯薬学 / 内科系臨床医学 / 消化器内科学

研究キーワード

  • 栄養
  • 慢性肝疾患

所属学会

  • 日本肝臓学会
  • 日本消化器病学会
  • 日本消化器内視鏡学会
  • 日本内科学会
  • 日本静脈経腸栄養学会

教育活動

授業担当

  1. 2018年, 学部専門, セメスター(後期), 医療行動学
  2. 2018年, 学部専門, 集中, 器官・システム病態制御学I
  3. 2018年, 学部専門, 集中, 臨床実習入門プログラム
  4. 2018年, 学部専門, 集中, 臨床実習・臨床実践学
  5. 2018年, 学部専門, 集中, アドバンスト医学実習
  6. 2018年, 学部専門, セメスター(前期), 内科学I

研究活動

学術論文(★は代表的な論文)

  1. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis, ONCOLOGY, 94巻, 4号, pp.215-pp.222, 2018
  2. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring, PLOS ONE, 13巻, 4号, APR 3 2018
  3. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48巻, 2号, pp.193-pp.204, FEB 2018
  4. Response criteria of tolvaptan for the treatment of hepatic edema, JOURNAL OF GASTROENTEROLOGY, 53巻, 2号, pp.258-pp.268, FEB 2018
  5. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53巻, 2号, pp.269-pp.280, FEB 2018
  6. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53巻, 1号, pp.107-pp.118, JAN 2018
  7. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 48巻, 1号, pp.51-pp.58, JAN 2018
  8. Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease, HEPATOLOGY RESEARCH, 48巻, 7号, pp.521-pp.528, JUN 2018
  9. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial, BMC CANCER, 18巻, JUN 4 2018
  10. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, HEPATOLOGY RESEARCH, 48巻, 4号, pp.264-pp.274, MAR 2018
  11. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib, ONCOLOGY, 92巻, 6号, pp.335-pp.346, 2017
  12. Efficacy and Safety of Daclatasvir Plus Asunaprevir Therapy for Chronic Hepatitis C Patients With Renal Dysfunction, JOURNAL OF MEDICAL VIROLOGY, 89巻, 4号, pp.665-pp.671, APR 2017
  13. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52巻, 4号, pp.504-pp.511, APR 2017
  14. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12巻, 8号, AUG 10 2017
  15. Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia, CLINICAL JOURNAL OF GASTROENTEROLOGY, 10巻, 4号, pp.383-pp.387, AUG 2017
  16. Differences in characteristics of glucose intolerance between patients with NAFLD and chronic hepatitis C as determined by CGMS, SCIENTIFIC REPORTS, 7巻, AUG 31 2017
  17. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury, JOURNAL OF GASTROENTEROLOGY, 52巻, 12号, pp.1252-pp.1257, DEC 2017
  18. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 52巻, 2号, pp.253-pp.262, FEB 2017
  19. Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection, HEPATOLOGY RESEARCH, 47巻, 8号, pp.767-pp.772, JUL 2017
  20. ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52巻, 6号, pp.746-pp.753, JUN 2017
  21. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52巻, 3号, pp.366-pp.375, MAR 2017
  22. Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 32巻, 3号, pp.645-pp.650, MAR 2017
  23. IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C, HEPATOLOGY RESEARCH, 47巻, 3号, pp.E5-pp.E13, MAR 2017
  24. Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid, HEPATOLOGY RESEARCH, 47巻, 10号, pp.1053-pp.1060, SEP 2017
  25. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46巻, 9号, pp.944-pp.948, AUG 2016
  26. Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases, HEPATOLOGY RESEARCH, 46巻, 13号, pp.1402-pp.1408, DEC 2016
  27. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization, ANTICANCER RESEARCH, 36巻, 7号, pp.3523-pp.3529, JUL 2016
  28. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients, HEPATOLOGY RESEARCH, 46巻, 8号, pp.758-pp.764, JUL 2016
  29. Preoperative Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Prediction of Microvascular Invasion in Small Hepatocellular Carcinoma, JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 40巻, 4号, pp.524-pp.530, JUL-AUG 2016
  30. Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus, HEPATOLOGY RESEARCH, 46巻, 3号, pp.E146-pp.E153, MAR 2016
  31. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31巻, 5号, pp.1009-pp.1015, MAY 2016
  32. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C, HEPATOLOGY RESEARCH, 46巻, 12号, pp.1256-pp.1263, NOV 2016
  33. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria, HEPATOLOGY RESEARCH, 46巻, 10号, pp.951-pp.963, SEP 2016
  34. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30巻, 4号, pp.726-pp.732, APR 2015
  35. Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report, TRANSPLANTATION PROCEEDINGS, 47巻, 3号, pp.809-pp.814, APR 2015
  36. Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases, EUROPEAN JOURNAL OF RADIOLOGY, 84巻, 8号, pp.1540-pp.1545, AUG 2015
  37. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 45巻, 6号, pp.607-pp.617, JUN 2015
  38. Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report, HEPATOLOGY RESEARCH, 45巻, 6号, pp.705-pp.710, JUN 2015
  39. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 45巻, 6号, pp.656-pp.662, JUN 2015
  40. Eicosapentaenoic acid/arachidonic acid ratio as a possible link between non-alcoholic fatty liver disease and cardiovascular disease, HEPATOLOGY RESEARCH, 45巻, 5号, pp.533-pp.539, MAY 2015
  41. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma, EUROPEAN RADIOLOGY, 25巻, 11号, pp.3272-pp.3281, NOV 2015
  42. Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation, HEPATOLOGY RESEARCH, 45巻, 11号, pp.1047-pp.1054, NOV 2015
  43. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma, JOURNAL OF DIGESTIVE DISEASES, 16巻, 9号, pp.505-pp.512, SEP 2015
  44. Two patients treated with PEGIFN/RBV/TVR triple therapy for recurrent hepatitis C after living donor liver transplantation, Hepatol Res, 20140101
  45. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49巻, 12号, pp.1548-pp.1556, DEC 2014
  46. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib, HEPATOLOGY RESEARCH, 44巻, 13号, pp.1320-pp.1328, DEC 2014
  47. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease, HEPATOLOGY RESEARCH, 44巻, 14号, pp.E420-pp.E427, DEC 2014
  48. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C, HEPATOLOGY RESEARCH, 44巻, 14号, pp.E447-pp.E454, DEC 2014
  49. Pilot Study of Stereotactic Body Radiation Therapy Combined with Transcatheter Arterial Chemoembolization for Small Hepatocellular Carcinoma, HEPATO-GASTROENTEROLOGY, 61巻, 129号, pp.31-pp.36, JAN-FEB 2014
  50. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients, HEPATOLOGY RESEARCH, 44巻, 7号, pp.740-pp.749, JUL 2014
  51. Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients, HEPATOLOGY RESEARCH, 44巻, 3号, pp.280-pp.287, MAR 2014
  52. Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus, HEPATO-GASTROENTEROLOGY, 61巻, 130号, pp.323-pp.328, MAR-APR 2014
  53. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29巻, 5号, pp.1035-pp.1042, MAY 2014
  54. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation, HEPATOLOGY RESEARCH, 44巻, 12号, pp.1259-pp.1264, NOV 2014
  55. Percutaneous Transvenous Embolization for Portal-Systemic Shunts associated with Encephalopathy: Long-term outcomes in 14 patients., Hepatol Res., 20130601
  56. The long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration.”,, J Gastroenterol Hepatol, 20131201
  57. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, J Gastroenterol, 20131201
  58. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28巻, 12号, pp.1834-pp.1841, DEC 2013
  59. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 48巻, 7号, pp.847-pp.855, JUL 2013
  60. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 48巻, 7号, pp.847-pp.855, JUL 2013
  61. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28巻, 3号, pp.530-pp.536, MAR 2013
  62. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases, HEPATOLOGY RESEARCH, 43巻, 11号, pp.1182-pp.1189, NOV 2013
  63. Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon alpha-2b to alpha-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report, INTERVIROLOGY, 55巻, 4号, pp.306-pp.310, 2012
  64. Evaluation of the mRECIST and alpha-Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib, ONCOLOGY, 83巻, 4号, pp.192-pp.200, 2012
  65. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation., J Gastroenterol Hepatol., 27巻, 9号, pp.1467-pp.1472, 20120901
  66. Recent trend of clinical features in patients with hepatocellular carcinoma, HEPATOLOGY RESEARCH, 42巻, 4号, pp.368-pp.375, APR 2012
  67. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 27巻, 12号, pp.1850-pp.1857, DEC 2012
  68. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-a for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava, HEPATOLOGY RESEARCH, 42巻, 5号, pp.442-pp.453, MAY 2012
  69. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy., J Gastroenterol., 46巻, 6号, pp.799-pp.808, 20110601
  70. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma., J Viral Hepat., 18巻, 10号, pp.e550-560, 20111001
  71. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region., Hepatol Res., 41巻, 11号, pp.1126-pp.1131, 20111101
  72. Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus., Hepatol Res., 41巻, 11号, pp.1046-pp.1056, 20111101
  73. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava., Hepatol Res., 20111201
  74. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy, JOURNAL OF GASTROENTEROLOGY, 46巻, 6号, pp.799-pp.808, JUN 2011
  75. Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus, HEPATOLOGY RESEARCH, 41巻, 11号, pp.1046-pp.1056, NOV 2011
  76. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region, HEPATOLOGY RESEARCH, 41巻, 11号, pp.1126-pp.1131, NOV 2011
  77. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma, JOURNAL OF VIRAL HEPATITIS, 18巻, 10号, pp.E550-pp.E560, OCT 2011
  78. Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: results and prognostic factors on long-term follow up., J Gastroenterol Hepatol., 25巻, 3号, pp.597-pp.604, 20100301
  79. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases., J Gastroenterol Hepatol., 25巻, 6号, pp.1117-pp.1122, 20100601
  80. Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and Lipiodol suspension for unresectable hepatocellular carcinoma., J Vasc Interv Radiol., 21巻, 8号, pp.1219-pp.1225, 20100801
  81. Pilot study of systemic combination therapy with S-1, an oral fluoropyrimidine, and cisplatin for hepatocellular carcinoma with extrahepatic metastases., Hepatogastroenterology., 57巻, 102-103号, pp.1272-pp.1278, 20100901
  82. Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems., Hepatol Res., 40巻, 11号, pp.1082-pp.1091, 20101101
  83. Evaluation of portosystemic collaterals by MDCT-MPR imaging for management of hemorrhagic esophageal varices., Eur J Radiol., 76巻, 2号, pp.239-pp.245, 20101101
  84. Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma., Hepatol Res., 40巻, 12号, pp.1195-pp.1203, 20101201
  85. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus., Scand J Gastroenterol., 45巻, 12号, pp.1488-pp.1496, 20101201
  86. Hypersensitivity Reactions to Transcatheter Chemoembolization with Cisplatin and Lipiodol Suspension for Unresectable Hepatocellular Carcinoma, JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 21巻, 8号, pp.1219-pp.1225, AUG 2010
  87. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: Analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus, SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 45巻, 12号, pp.1488-pp.1496, DEC 2010
  88. Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma, HEPATOLOGY RESEARCH, 40巻, 12号, pp.1195-pp.1203, DEC 2010
  89. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 25巻, 6号, pp.1117-pp.1122, JUN 2010
  90. Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: Results and prognostic factors on long-term follow up, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 25巻, 3号, pp.597-pp.604, MAR 2010
  91. Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems, HEPATOLOGY RESEARCH, 40巻, 11号, pp.1082-pp.1091, NOV 2010
  92. Evaluation of portosystemic collaterals by MDCT-MPR imaging for management of hemorrhagic esophageal varices, EUROPEAN JOURNAL OF RADIOLOGY, 76巻, 2号, pp.239-pp.245, NOV 2010
  93. Pilot Study of Systemic Combination Therapy with S-1, an Oral Fluoropyrimidine, and Cisplatin for Hepatocellular Carcinoma with Extrahepatic Metastases, HEPATO-GASTROENTEROLOGY, 57巻, 102-03号, pp.1272-pp.1278, SEP-OCT 2010
  94. Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient., Hepatol Res., 39巻, 4号, pp.415-pp.420, 20090101
  95. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis., J Gastroenterol., 44巻, 5号, pp.492-pp.502, 20090301
  96. The first Japanese case of COACH syndrome., Hepatol Res., 39巻, 3号, pp.318-pp.323, 20090301
  97. Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma., Cardiovasc Intervent Radiol., 32巻, 4号, pp.687-pp.694, 20090701
  98. Successful treatment of pulmonary metastases associated with advanced hepatocellular carcinoma by systemic 5-fluorouracil combined with interferon-alpha in a hemodialysis patient, HEPATOLOGY RESEARCH, 39巻, 4号, pp.415-pp.420, APR 2009
  99. Transarterial Infusion Chemotherapy Using Cisplatin-Lipiodol Suspension With or Without Embolization for Unresectable Hepatocellular Carcinoma, CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 32巻, 4号, pp.687-pp.694, JUL 2009
  100. The first Japanese case of COACH syndrome, HEPATOLOGY RESEARCH, 39巻, 3号, pp.318-pp.323, MAR 2009
  101. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis, JOURNAL OF GASTROENTEROLOGY, 44巻, 5号, pp.492-pp.502, MAY 2009
  102. A Case of Fulminant Hepatic Failure Caused by Hepatitis E virus79117, Clinical Journal of gastroenterology, 1巻, pp.69-pp.74, 20080603
  103. Etiology and outcome of acute liver failure: retrospective analysis of 50 patients treated at a single center., J Gastroenterol Hepatol., 23巻, 8pt1号, pp.1216-pp.1222, 20080701
  104. Etiology and outcome of acute liver failure: Retrospective analysis of 50 patients treated at a single center, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 23巻, 8号, pp.1216-pp.1222, AUG 2008
  105. Balloon-occluded retrograde transvenous obliteration for portal-systemic encephalopathy due to superior mesenteric-caval shunt via the right gonadal vein, INTERNAL MEDICINE, 46巻, 17号, pp.1479-pp.1480, 2007
  106. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma., World J Gastroenterol., 13巻, 3号, pp.414-pp.420, 20070101
  107. Balloon-occluded retrograde transvenous obliteration for portal-systemic encephalopathy due to superior mesenteric-caval shunt via the right gonadal vein., Intern Med., 46巻, 17号, pp.1479-pp.1480, 20070901
  108. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma., Liver International., 27巻, 9号, pp.1209-pp.1216, 20071101
  109. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma, WORLD JOURNAL OF GASTROENTEROLOGY, 13巻, 3号, pp.414-pp.420, JAN 21 2007
  110. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma, LIVER INTERNATIONAL, 27巻, 9号, pp.1209-pp.1216, NOV 2007
  111. Cell-specific inhibition of paramyxovirus maturation by proteasome inhibitors, MICROBIOLOGY AND IMMUNOLOGY, 49巻, 9号, pp.835-pp.844, 2005

著書等出版物

  1. 2017年,5月, 臨牀 消化器内科, 肝疾患におけるサルコペニアとその発生メカニズム, 2017年, 単行本(学術書), 共著, 517-524
  2. 2016年12月, 特集 座談会 肝疾患におけるサルコペニアの判定基準(第1版), 肝臓, 2016年, 共著, 西口 修平;日野 啓輔;森屋 恭爾;白木 亮;平松 憲;西川 浩樹
  3. 2016年07月, 肝疾患におけるサルコペニアの判定基準(第1版), 肝臓, 2016年, 共著, 西口 修平;日野 啓輔;森屋 恭爾;白木 亮;平松 憲;西川 浩樹
  4. 2016年03月, 当院における多職種連携による脂肪肝患者への取り組み, 国立大学リハビリテーション療法士学術大会誌, 2016年, 共著, 筆保 健一;河江 敏広;福原 幸樹;岩城 大介;中島 勇樹;平松 憲;伊藤 義広;三上 幸夫;木村 浩彰
  5. 2016年,6月,1日, 肝硬変におけるサルコペニアの現状と対策, 臨床栄養, 医歯薬出版株式会社, 2016年, 6, 共著
  6. 2016年,2月,2日, 肝硬変の予後予測における筋肉萎縮の重要性:CTの腸腰筋の厚さを利用した検討, メディカルレビュー社, 2016年, 2, 共著
  7. 2013年-0月, 症例報告 ゲノタイプ3a型のC型急性肝炎の1例 : IL28B遺伝子からの考察, 肝臓, 小林 知樹;川上 由育;平松 憲 他;平松 憲
  8. 2012年-1月, 肝外転移合併肝細胞癌に対する全身/動注化学療法を主体とした集学的治療の成績, 消化器内科 / 消化器内科編集委員会 編, 平松 憲;相方 浩;宮木 大輔 他;宮木 大輔

招待講演、口頭・ポスター発表等

  1. サルコペニア判定基準の妥当性と問題点, 平松 憲, 第54回日本肝臓学会総会, 2018年06月14日, 通常, 日本語, 大阪市
  2. 肝硬変患者のサルコペニアに及ぼすカルニチンの効果に関する検討, 平松 憲, 第104回日本消化器病学会総会, 2018年04月19日, 通常, 日本語, 東京
  3. 肝硬変の病態と薬物治療マネージメント, 平松 憲, 第2回水島肝疾患フォーラム, 2017年12月07日, 通常, 日本語, 倉敷市
  4. 慢性肝疾患患者における筋肉量と筋力の相関に関する検討, 平松 憲, 第42回日本肝臓学会西部会, 2017年11月30日, 通常, 日本語, 福岡市
  5. 肝硬変患者のサルコペニアに及ぼすカルニチンの効果に関する検討, 平松 憲, 第108回日本消化器病学会中国支部例会, 2017年11月25日, 通常, 日本語, 宇部市
  6. 肝硬変患者におけるサルコペニアに対するカルニチンの使用経験, 平松 憲, OTSUKA Liver Forum 2017, 2017年11月18日, 通常, 日本語, 東京
  7. 肝硬変患者のサルコペニアに及ぼすカルニチンの効果, 平松 憲, JDDW2017, 2017年10月12日, 通常, 日本語, 福岡市
  8. 肝硬変のマネジメント~サルコペニアを中心に~, 平松 憲, 肝疾患トータルマネジメントを考える会, 2017年09月28日, 通常, 日本語, 仙台市
  9. 肝硬変患者のサルコペニアに対するレボカルニチンの効果に関する検討, 平松 憲, 第53回日本肝臓学会総会, 2017年06月08日, 通常, 日本語
  10. 慢性肝疾患におけるサルコペニア, 平松 憲, サルコペニアを考える会, 2017年05月25日, 通常, 日本語, 大崎市
  11. サルコペニア肥満を伴う慢性肝疾患に対する栄養・運動療法に関する検討, 平松 憲, 第103回日本消化器病学会総会, 2017年04月20日, 通常, 日本語, 東京
  12. 肝硬変のトータルマネージメント, 平松 憲, 香川肝疾患学術講演会, 2017年03月10日, 招待, 日本語, 高松市
  13. 慢性肝疾患患者における血糖変動-CGMを用いた検討, 平松 憲, Meet the Expert, 2017年02月24日, 通常, 日本語, 広島市
  14. 肝硬変における腹水評価~ガイドラインから診る腹水治療戦略~, 平松 憲, 消化器内科講演会 スペシャル, 2017年02月17日, 通常, 日本語, 広島市
  15. The effect of Carnitine on sarcopenia and liver function in patients with liver cirrhosis, Akira Hiramatsu, International Liver Symposium 2017, 2017年02月04日, 通常, 英語, Kyoto
  16. 肝疾患におけるサルコペニアの診断基準と対策, 平松 憲, 肝臓栄養講演会, 2016年12月21日, 通常, 日本語, 広島市
  17. 肝硬変のトータルマネージメント, 平松 憲, 学術講演会~肝硬変を考える~, 2016年10月26日, 通常, 日本語, 福山市
  18. ウイルス性肝炎以外の肝疾患, 平成28年度ひろしま肝疾患コーディネーター養成講座, 2016年10月22日, 通常, 日本語, 広島市
  19. 広島大学における腹水評価統一化に向けての検討結果~外部検証を含めて~, 平松 憲, 肝疾患エキスパートによる腹水評価アドバイザリーミーティング, 2016年09月17日, 通常, 日本語, 東京都
  20. 慢性肝疾患におけるサルコペニアの現状と対策, 平松 憲, 第1回札幌サルコペニアを考える会, 2016年07月21日, 通常, 日本語, 札幌市
  21. 糖尿病合併肝硬変患者における持続血糖測定の有用性に関する検討, 平松 憲, 会議名(日) 第52回日本肝臓学会総会, 2016年05月19日, 通常, 日本語, 東京都
  22. 肝硬変患者に対する栄養マネージメント, 平松 憲, 第102回日本消化器病学会総会, 2016年04月22日, 通常, 日本語, 東京都
  23. "Measurement of muscle mass using CT is useful to diagnose sarcopenia in patients with cirrhosis Abstract Body", 第25回アジア太平洋肝臓病学会議(APASL)年次総会, 2016年02月20日, 通常, 英語
  24. 肝硬変患者におけるサルコぺニア;BIA法とCT法の相関性に関する検討, 第41回日本肝臓学会西部会, 2015年12月03日, 通常, 日本語
  25. 持続血糖測定を用いた肝硬変患者の血糖コントロールに関する検討, 第103回日本消化器病学会中国支部例会, 2015年06月13日, 通常, 日本語
  26. 難治性腹水を伴う肝硬変患者におけるトルバプタンの有効性と安全性に関する検討, 第51回日本肝臓学会総会, 2015年05月21日, 通常, 日本語
  27. 肝硬変のトータルマネージメント:栄養管理、合併症対策を中心に, 第28回岡山協立病院地域医療連携講演会, 2015年05月08日, 招待, 日本語
  28. 肝硬変の栄養療法、最新の治療戦略に関して, 第28回岡山市中区地域連携講演会, 2015年04月24日, 招待, 日本語
  29. 広島大学での事例, 平松 憲, 第3回 肝とサルコペニアを考える会, 2015年04月04日, 招待, 日本語, 東京都
  30. 肝外転移合併肝細胞癌に対する全身/動注化学療法を主体とした集学的治療の成績, 平松 憲, 第15回 日本肝臓学会大会, 2011年, 通常, 日本語

社会活動

委員会等委員歴

  1. 日本肝臓学会 サルコペニア判定基準作成WG委員, 2015年07月01日

その他社会貢献活動(広大・部局主催含)

  1. 肝疾患診療連携拠点病院市民公開講座, 肝硬変における栄養~意外と大事な栄養と運動~, 2017年/06月/11日, 2017年/06月/11日, 講師, 講演会, 社会人・一般

学術雑誌論文査読歴

  1. 2018年, Internal Medicine, その他, 査読者, 1
  2. 2017年, Hepatology Reserch, その他, 査読者, 1
  3. 2017年, Molecular and Clinical Oncology, その他, 査読者, 1